Synairgen plc Company Profile (LON:SNG)

About Synairgen plc

Synairgen plc logoSynairgen plc is a holding company. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models. The Company's primary asset is AZD9412, which is an inhaled interferon beta (IFN-beta) therapy. AZD9412 is outlicensed to AstraZeneca for the clinical development and commercialization, and is in a confirmatory Phase II trial. Its drug programs include IFN-b (SNG001) for Asthma and COPD, and Lysyl oxidase-like protein 2 (LOXL2) inhibitors for IPF. The Company's subsidiary includes Synairgen Research Limited, which is engaged in the drug discovery and development.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: SNG
  • CUSIP:
Key Metrics:
  • Previous Close: $0.34
  • 50 Day Moving Average: $19.17
  • 200 Day Moving Average: $23.15
  • 52-Week Range: GBX 12.10 - GBX 38
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $25.12M
  • Outstanding Shares: 91,340,000
Additional Links:

Analyst Ratings

Consensus Ratings for Synairgen plc (LON:SNG) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 91.50

Analysts' Ratings History for Synairgen plc (LON:SNG)
DateFirmActionRatingPrice TargetDetails
11/29/2016FinnCapReiterated RatingCorporateGBX 137View Rating Details
9/22/2016N+1 SingerLower Price TargetBuyGBX 47 -> GBX 46View Rating Details
(Data available from 2/20/2015 forward)


Earnings History for Synairgen plc (LON:SNG)
No earnings announcements for this company have been tracked by


Earnings Estimates for Synairgen plc (LON:SNG)
Current Year EPS Consensus Estimate: $-4.12 EPS


Dividend History for Synairgen plc (LON:SNG)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Synairgen plc (LON:SNG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/11/2015Shaw,Simon J BInsiderBuy65,217GBX 23£14,999.91
(Data available from 1/1/2013 forward)


Latest Headlines for Synairgen plc (LON:SNG)
News IconTechnical Indicator Review on Shares of Synairgen PLC (SNG.L) - Providence Standard (LON:SNG) - February 15 at 6:05 AM
News IconStock Watch: Indicators in View for Synairgen PLC (SNG.L) - Springdale Times (LON:SNG) - January 22 at 12:42 AM
News IconSynairgen Plc SNG Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (LON:SNG) - January 8 at 1:06 AM
News IconToday's Shorts Alert: Synairgen plc (SNG) Declined -7.07% on Dec 20 - Herald KS (LON:SNG) - December 20 at 8:28 PM logoAstraZeneca likely to adapt clinical trial of Synairgen drug (LON:SNG) - October 13 at 11:13 AM
News IconSynairgen says AstraZeneca stops mid-stage asthma drug study (LON:SNG) - October 12 at 10:35 AM
News IconSynairgen: AstraZeneca has Stopped Asthma Drug Trial (LON:SNG) - October 12 at 10:35 AM logo“Not the end of the road” for Synairgen’s asthma treatment (LON:SNG) - October 12 at 10:35 AM logoAZD9412 Clinical Trial Update (LON:SNG) - October 12 at 10:35 AM logoSynairgen on schedule with all of its drug programmes (LON:SNG) - September 22 at 7:01 PM logoHalf Year 2016 Synairgen PLC Earnings Release - Before Market Open (LON:SNG) - September 22 at 12:10 PM logoSynairgen Plc :SNG-GB: Earnings Analysis: 2015 By the Numbers : August 11, 2016 (LON:SNG) - August 11 at 10:48 AM logoSynairgen Plc (SNG) - Financial and Strategic SWOT Analysis Review - New Market Report (LON:SNG) - June 29 at 10:15 AM logoSynairgen : Results of 2016 Annual General Meeting (LON:SNG) - June 15 at 11:52 AM logoSynairgen Plc :SNG-GB: Earnings Analysis: 2015 By the Numbers (LON:SNG) - March 29 at 9:10 PM logoFull Year 2015 Synairgen PLC Earnings Release - Before Market Open (LON:SNG) - March 22 at 7:07 AM logoPositive LOXL2 results (LON:SNG) - March 22 at 3:45 AM logoSynairgen plc - Synairgen and Pharmaxis announce research collaboration to develop LOXL2 inhibitor for pulmonary fibrosis (LON:SNG) - August 5 at 9:04 AM logoPharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis (LON:SNG) - August 5 at 12:02 AM


What is Synairgen plc's stock symbol?

Synairgen plc trades on the London Stock Exchange (LON) under the ticker symbol "SNG."

Where is Synairgen plc's stock going? Where will Synairgen plc's stock price be in 2017?

1 brokers have issued 1 year price objectives for Synairgen plc's shares. Their predictions range from GBX 46 to GBX 137. On average, they expect Synairgen plc's stock price to reach GBX 91.50 in the next twelve months.

When will Synairgen plc announce their earnings?

Synairgen plc is scheduled to release their next quarterly earnings announcement on Monday, March, 20th 2017.

How do I buy Synairgen plc stock?

Shares of Synairgen plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of Synairgen plc stock cost?

One share of Synairgen plc stock can currently be purchased for approximately GBX 27.50.

Last Updated on 2/20/2017 by Staff